Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11578567 | 0.80 | NLRP3 (0.43) | NLRP3MAPK8PGK1PKMLATS1 | |
| SCHEMBL21360997 | 0.80 | PGK1 (0.36) | PGK1LATS1LATS2 | |
| SCHEMBL1978195 | 0.77 | PGK1 (0.39) | NLRP3MAPK8PGK1LMNAPDE10A | |
| SCHEMBL30657526 | 0.77 | PGK1 (0.39) | NLRP3MAPK8PGK1LMNAPDE10A | |
| SCHEMBL11580569 | 0.76 | PKM (0.39) | NLRP3MAPK8PGK1LMNAPKM | |
| SCHEMBL31467246 | 0.75 | PSIP1 (0.41) | LMNAL3MBTL1 | |
| SCHEMBL5743844 | 0.70 | PGK1 (0.49) | PGK1LMNAL3MBTL1 | |
| SCHEMBL11234919 | 0.70 | HDAC2 (0.49) | NLRP3PGK1LATS1LATS2CYP1A2 | |
| SCHEMBL2415601 | 0.69 | CXCR4 (0.41) | LMNACYP1A2L3MBTL1 | |
| SCHEMBL24765256 | 0.67 | NUDT1 (0.46) | NLRP3MAPK8PGK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| EP-1655300-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1294720-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-04-05 | — | — | EP | disclosed |
| EP-1294720-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-03-26 | — | — | EP | disclosed |
| US-6420359-B1 | 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
| WO-2001096338-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | NLRP3 4254/4885MAPK8 4349/4885PGK1 2487/4885 |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | NLRP3 4761/4885MAPK8 3848/4885PGK1 1100/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | NLRP3 4254/4885MAPK8 4349/4885PGK1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.